Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm

Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive malignancy with poor outcomes. Although novel options like tagraxofusp, a CD123-directed cytotoxin, has emerged and is promising, treatment options are very limited in the relapsed and recurrent setting. We present a case of r...

Full description

Bibliographic Details
Main Authors: Prashanth Ashok Kumar MBBS, Mulham Ombada MBBS, Gayatri Pemmasani MBBS, Ajay Tambe MBBS, Katalin Banki MD, Teresa Gentile MD, PhD
Format: Article
Language:English
Published: SAGE Publishing 2022-11-01
Series:Journal of Investigative Medicine High Impact Case Reports
Online Access:https://doi.org/10.1177/23247096221127114

Internet

https://doi.org/10.1177/23247096221127114

Similar Items